Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
Abstract Metastatic breast cancer (BC) is considered incurable, and it is generally treated with sequential single-agent therapies to control it with palliative intent. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are used in the front-line setting of hormone receptor (HR)-positive, HER2-negativ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2020-09-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-020-00126-0 |
| _version_ | 1819089261625868288 |
|---|---|
| author | Isabella O. Wender Kayla Haines Mohammad Jahanzeb |
| author_facet | Isabella O. Wender Kayla Haines Mohammad Jahanzeb |
| author_sort | Isabella O. Wender |
| collection | DOAJ |
| description | Abstract Metastatic breast cancer (BC) is considered incurable, and it is generally treated with sequential single-agent therapies to control it with palliative intent. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are used in the front-line setting of hormone receptor (HR)-positive, HER2-negative BC, and guidelines discourage the use of a second-line CDK4/6i after failure of first-line use of this class of drugs due to lack of data supporting this practice. We report a case of a postmenopausal woman with HR-positive and HER2-negative advanced BC who was treated with four lines of hormonal therapy and more than five chemotherapy regimens, with progression. Palbociclib was used in the sixth-line therapy and discontinued after 5 months. We then tried abemaciclib in the 11th-line setting, where it induced a response that lasted 16 months. |
| first_indexed | 2024-12-21T22:05:08Z |
| format | Article |
| id | doaj.art-a19b8281746a4b8db5a50ed987362768 |
| institution | Directory Open Access Journal |
| issn | 2366-1070 2366-1089 |
| language | English |
| last_indexed | 2024-12-21T22:05:08Z |
| publishDate | 2020-09-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj.art-a19b8281746a4b8db5a50ed9873627682022-12-21T18:48:44ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892020-09-018235135810.1007/s40487-020-00126-0Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature ReviewIsabella O. Wender0Kayla Haines1Mohammad Jahanzeb2Escola de Medicina da Pontifícia, Universidade Católica do Rio Grande do Sul (PUC-RS)Florida Precision Oncology, a Division of 21st Century OncologyFlorida Precision Oncology, a Division of 21st Century OncologyAbstract Metastatic breast cancer (BC) is considered incurable, and it is generally treated with sequential single-agent therapies to control it with palliative intent. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are used in the front-line setting of hormone receptor (HR)-positive, HER2-negative BC, and guidelines discourage the use of a second-line CDK4/6i after failure of first-line use of this class of drugs due to lack of data supporting this practice. We report a case of a postmenopausal woman with HR-positive and HER2-negative advanced BC who was treated with four lines of hormonal therapy and more than five chemotherapy regimens, with progression. Palbociclib was used in the sixth-line therapy and discontinued after 5 months. We then tried abemaciclib in the 11th-line setting, where it induced a response that lasted 16 months.https://doi.org/10.1007/s40487-020-00126-0Breast carcinomaCyclin-dependent kinaseMetastatic breast cancer |
| spellingShingle | Isabella O. Wender Kayla Haines Mohammad Jahanzeb Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review Oncology and Therapy Breast carcinoma Cyclin-dependent kinase Metastatic breast cancer |
| title | Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review |
| title_full | Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review |
| title_fullStr | Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review |
| title_full_unstemmed | Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review |
| title_short | Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review |
| title_sort | response to abemaciclib after 10 lines of therapy including palbociclib in metastatic breast cancer a case report with literature review |
| topic | Breast carcinoma Cyclin-dependent kinase Metastatic breast cancer |
| url | https://doi.org/10.1007/s40487-020-00126-0 |
| work_keys_str_mv | AT isabellaowender responsetoabemaciclibafter10linesoftherapyincludingpalbociclibinmetastaticbreastcanceracasereportwithliteraturereview AT kaylahaines responsetoabemaciclibafter10linesoftherapyincludingpalbociclibinmetastaticbreastcanceracasereportwithliteraturereview AT mohammadjahanzeb responsetoabemaciclibafter10linesoftherapyincludingpalbociclibinmetastaticbreastcanceracasereportwithliteraturereview |